Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 30, 2015British Journal of HaematologyOpen Access

Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAdam J. MeadDMDragana MilojkovićSKSteven Knapper

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mead et al. (2015) studied this question.

synapsesocial.com/papers/6a0ffef457bfcc72645fca65https://doi.org/10.1111/bjh.13379
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment2008 · 95 citations
  2. 2The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)2006 · 402 citations
  3. 3A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders2005 · 3,491 citations
  4. 4Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis2013 · 430 citations
  5. 5The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes2009 · 4,458 citations